GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The companys wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.
GSK Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for GSK, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Glaxosmithkline Plc ranked in the 36th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for GSK, they are:
The company has produced more trailing twelve month cash flow than 94.58% of its sector Healthcare.
Glaxosmithkline Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 22.84% of tickers in our DCF set.
GSK's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 22.84% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as GSK, try TMO, ITGR, OFIX, PKI, and HOLX.
A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than US$235 million for infringing a patent for its blood pressure drug Coreg.
DUBLIN--(BUSINESS WIRE)--The "Pneumonia Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Pneumonia Therapeutics Market to Reach US$22.5 Billion by the Year 2027 Amid the COVID-19 crisis, the global market for Pneumonia Therapeutics estimated at US$14.5 Billion in the year 2020, is projected to reach a revised size of US$22.5 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027. Drugs, one of the
A new research study from “Data Bridge Market Research” with title Leigh Syndrome Treatment Insights 2020GlaxoSmithKline Plc, Brother Enterprises, Huazhong, Zhejiang Tianxin, Stryker Corporation, Zimmer Biomet Holdings, Inc., Wright Medical Technology, Inc., Integra LifeSciences Holdings Corporation among other domestic
A new market study is released on Global Fabry Disease market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Fabry Disease market report